Nearly two-thirds of American osteoporotic hip fractures are seen in the extreme elderly
Threat of epidemic as this population increases
2012-06-08
(Press-News.org) Berlin, Germany, June 7 2012: A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
Via the Nationwide Inpatient Sample (NIS), 4.3 million patients over the age of 65 with osteoporotic hip fractures were studied. Results showed that 67.3% of hip fractures occurred in the extreme elderly, increasing from 172,209 in 1993 to 180,428 in 2008. This growth was despite the fact that hip fracture prevalence decreased from 2,236 to 1,600 per 1,000 person-years in the same period, but is coincident with the dramatic rise in the extreme elderly population, from 7.7 million in 1993 to 11.2 million in 2008.
In addition, in 2008, the extreme elderly made up 42.3% of the elderly population, but accounted for 69% of hospitalisations. "We know that hip fracture in the extreme elderly is a serious problem due to the associated consequences of hospitalisation, disability and mortality," commented Ms. Amrita Sehgal from University of California, USA and lead study author. "This data is cause for concern as the impact highlighted will only increase along with this population segment. The question now is how we manage the extreme elderly more effectively to limit the impact that osteoporotic fractures have going forward."
With the extreme elderly predicted to comprise 25% of the total US population by 2050, this study calls for more aggressive measures to be introduced to enable osteoporosis to be more effectively prevented, diagnosed and treated. The study recommends that this should be via traditional methods, e.g. medical professionals, or more holistically via non-traditional settings and providers, like assisted living facilities.
Abstract Number: OP0043
###
NOTES TO EDITORS:
For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress Press Office in Hall 6 on the 3rd floor of the Congress Centre during EULAR 2012 or on:
Email: eularpressoffice@cohnwolfe.com
Candice Debleu:
Onsite tel: +44 7894 386 425
About EULAR
The European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations
In line with The European Union of Medical Specialists (UEMS), EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems
EULAR aims to promote, stimulate and support the research, prevention, treatment and rehabilitation of rheumatic diseases. With 45 scientific member societies, 36 PARE organisations and 10 health professionals associations, EULAR underscores the importance of combating rheumatic diseases not only by medical means, but also through a wider context of care for rheumatic patients and a thorough understanding of their social and other needs
Diseases of the bone and joints such as rheumatoid arthritis and osteoarthritis cause disability in 4-5% of the adult population and are predicted to rise as people live longer
EULAR 2012 is set to be the biggest rheumatology event in Europe with over 15,000 scientists, physicians, allied health professionals, and related audiences in attendance from over 115 countries. Over the course of the congress, more than 275 oral and 1400 poster abstract presentations will be featured, with 1,010 invited speaker lectures taking place in 190 sessions
To find out more about the activities of EULAR, visit: www.eular.org
END
ELSE PRESS RELEASES FROM THIS DATE:
2012-06-08
Berlin, Germany, June 7 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20* response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo.
This randomised, placebo controlled, 24 week period of an ongoing Phase III study of 409 patients indicated that more patients treated with both doses of CZP achieved ACR50* and ACR70* response ...
2012-06-08
Berlin, Germany, June 7 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab).
Results of the German study ...
2012-06-08
Berlin, Germany, June 7 2012: Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.
"Anti-TNFs, such as infliximab, adalimumab and etanercept have become the treatment of choice for patients with inflammatory rheumatic diseases who ...
2012-06-08
Berlin, Germany, June 7 2012: Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20*.
The Phase IIIb AMPLE study (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) was carried out in 646 biologic-naïve patients with active RA and inadequate response to methotrexate. ...
2012-06-08
All nuclear energy and weapons programs should be independently regulated and subject to rigorous peer review, according to three experts on nuclear policy. Their comments and recommendations are published in an article entitled, "A Safer Nuclear Enterprise," in the June 8 issue of the journal Science.
The authors noted that, despite international diplomatic efforts to prevent the proliferation of nuclear weapons and ensure that nuclear material is protected against theft, there is growing apprehension about terrorists acquiring weapons or nuclear material.
"There is ...
2012-06-08
When you are planning a vacation or a trip and you need to rent a car, one of the most important things that you should consider is whether or not you need to buy rental car insurance. When you search for a car rental company online or in person, most salespeople will tell you that you need insurance, while most web pages will tell you that you do not need it. This couldn't be further from the truth. In reality, purchasing rental car insurance for a few extra dollars per day may be one of the most intelligent things that a person can do for themselves.
CheapCarInsurance.net ...
2012-06-08
An international research team led by the University of Colorado Boulder has generated the first laser-like beams of X-rays from a tabletop device, paving the way for major advances in many fields including medicine, biology and nanotechnology development.
For half a century, scientists have been trying to figure out how to build a cost-effective and reasonably sized X-ray laser that could, among other things, provide super-high-resolution imaging, according to Henry Kapteyn, a CU-Boulder physics professor and fellow at JILA, a joint institute of CU-Boulder and the National ...
2012-06-08
New York, NY (June 7, 2012) — Researchers at Columbia University Medical Center (CUMC) have identified a brain receptor that appears to play a central role in regulating appetite. The findings, published today in the online edition of Cell, could lead to new drugs for preventing or treating obesity.
"We've identified a receptor that is intimately involved in regulating food intake," said study leader Domenico Accili, MD, professor of Medicine at CUMC. "What is especially encouraging is that this receptor is belongs to a class of receptors that turn out to be good targets ...
2012-06-08
Chemical reactions on the surface of metal oxides, such as titanium dioxide and zinc oxide, are important for applications such as solar cells that convert the sun's energy to electricity. Now University of Washington scientists have found that a previously unappreciated aspect of those reactions could be key in developing more efficient energy systems.
Such systems could include, for example, solar cells that would produce more electricity from the sun's rays, or hydrogen fuel cells efficient enough for use in automobiles, said James Mayer, a UW chemistry professor.
"As ...
2012-06-08
New research published today in BioMed Central's open access journal BMC Genomics reveals that the Malaysian parasitic plant Rafflesia cantleyi, with its 50cm diameter flowers, has 'stolen' genes from its host Tetrastigma rafflesiae. Analysis of these genes shows that their functions range from respiration to metabolism, and that some of them have even replaced the parasites own gene activity.
Vertical gene transfer is that between parents and their offspring, while horizontal gene transfer is the movement of genes between two different organisms. Bacteria use horizontal ...
LAST 30 PRESS RELEASES:
[Press-News.org] Nearly two-thirds of American osteoporotic hip fractures are seen in the extreme elderly
Threat of epidemic as this population increases
